Fumaric Acid Esters in Severe Ulcerative Necrobiosis Lipoidica: A Case Report and Evaluation of Current Therapies

Fumaric acid esters in severe ulcerative necrobiosis lipoidica: a case report and evaluation of current therapies.

Sir, Necrobiosis lipoidica (NL) was first described by Oppenheim in 1929. NL is a granulomatous skin disease with association with diabetes mellitus (DM) in 10–40% of cases, but less than 1% of patients with DM develop NL. Additional risk factors for NL include other granulomatous diseases, such as granuloma anulare (GA), sarcoidosis, colitis ulcerosa and Crohn’s disease. Middleaged women are m...

A severe case of ulcerating necrobiosis lipoidica.

Necrobiosis Lipoidica Diabeticorum of the Scalp: A Case Report

Necrobiosis lipoidica diabeticorum (NLD) is a rare chronic and granulomatous skin disorder that affects 0.3% of diabetic patients. Although the etiology and pathogenesis of NLD is still contraversial, it is thought that microangipathy has an important role. The legs are the most common site for NLD, but involvement of other areas such as the abdomen, upper extremities and scalp have been report...

Ustekinumab to target granulomatous dermatitis in recalcitrant ulcerative necrobiosis lipoidica: case report and proposed mechanism.

We present a 42-year-old woman with no history of diabetes or glucose intolerance who had a 5-year history of ulcerative necrobiosis lipoidica (NL). Despite failure of multiple medications, she experienced clearing of her ulcers after her treatment was changed to ustekinumab. We discuss our patient's disease course and elaborate upon mechanistic reasons for her improvement related to ustekinuma...

Treatment of refractory ulcerative necrobiosis lipoidica diabeticorum with infliximab: report of a case.

BACKGROUND Necrobiosis lipoidica diabeticorum (NLD) is a rare, granulomatous inflammatory skin disease of unknown origin, sometimes associated with diabetes mellitus. Skin lesions usually develop on the lower extremities and can progress toward ulceration and scarring. Many treatments have been proposed, but few have demonstrated consistent efficacy, and no standard regimens have emerged to dat...